Recent Updates — BMGL

Following the sale of 6,000,000 units in a prior offering, Basel Medical Group Ltd received exercise notices for all associated Common Warrants. The company issued 6,000,000 new Ordinary Shares to satisfy these exercises using the zero cash exercise option. No proceeds were raised from this transaction. As of October 29, 2026, total ordinary shares outstanding increased to 13,582,111. Basel Medical Group Ltd operates in the healthcare sector.

Basel Medical Group Ltd closed a registered direct offering on October 9, 2026, issuing and selling 6,000,000 units at a public price of US$1.33 per unit. The transaction generated gross proceeds of US$7.98 million and estimated net proceeds of approximately US$7.28 million after deducting commissions and offering expenses. Each unit consists of one ordinary share or pre-funded warrant and one common warrant exercisable at 110% of the offering price, with a five-year term and a zero cash exercise option available to holders. Proceeds are intended for general working capital, mergers and acquisitions, and other corporate purposes. Basel Medical Group Ltd operates as a Singapore-based provider of orthopedic, trauma, sports medicine, and neurosurgical services.

Basel Medical Group Ltd priced a registered direct offering of 6,000,000 units at US$1.33 per unit, raising up to US$7.98 million in gross proceeds and approximately US$7.28 million in net proceeds. Each unit consists of one ordinary share or pre-funded warrant and one common warrant exercisable for an additional ordinary share. The company intends to use the net proceeds for general working capital, mergers and acquisitions, and other corporate purposes. Basel Medical Group Ltd operates as a Singapore-based provider of orthopedic, trauma, sports medicine, and neurosurgical healthcare services.

Basel Medical Group Ltd announced changes to its board of directors. Outgoing directors Mr. Fung Keng Leong and Mr. Tan Boon Chye stepped down with immediate effect, though Mr. Tan will remain as chief commercial officer. The board appointed three new members: Mr. Yang Xinwen, Ms. Cao Juan, and Mr. Frederick Hong Shieh Ming (independent). The company states these appointments aim to broaden expertise in healthcare, business operations, capital markets, and investment advisory to support strategic growth. Basel Medical Group Ltd operates in the healthcare sector.

Basel Medical Group Ltd announced it has regained compliance with the Nasdaq minimum bid price requirement. This follows a period of non-compliance regarding the minimum share price threshold. The company operates in the healthcare industry, focusing on medical services and products.